FY2027 EPS Estimates for Precigen Lowered by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Investment analysts at HC Wainwright cut their FY2027 earnings per share estimates for shares of Precigen in a research note issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.18 per share for the year, down from their prior estimate of $0.20. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.66 EPS.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $1.19 million during the quarter, compared to analysts' expectations of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Separately, JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Remove Ads

Precigen Stock Performance

Shares of NASDAQ PGEN traded down $0.11 during trading hours on Friday, hitting $1.71. 1,732,682 shares of the stock were exchanged, compared to its average volume of 1,175,229. The company's fifty day simple moving average is $1.64 and its two-hundred day simple moving average is $1.17. The company has a market cap of $502.81 million, a PE ratio of -3.11 and a beta of 1.58. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17.

Hedge Funds Weigh In On Precigen

A number of institutional investors have recently added to or reduced their stakes in PGEN. State Street Corp grew its stake in shares of Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock worth $2,720,000 after buying an additional 29,253 shares during the last quarter. LexAurum Advisors LLC boosted its holdings in shares of Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock valued at $775,000 after acquiring an additional 417,055 shares in the last quarter. Iridian Asset Management LLC CT grew its position in Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock worth $5,871,000 after acquiring an additional 1,465,962 shares during the last quarter. Geode Capital Management LLC raised its position in Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock valued at $3,075,000 after purchasing an additional 149,829 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 15,680 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.